Directory · US
Biotechnology in United States
A register of firms and the professionals working at them in the Biotechnology sector based in United States. Browse the public index, then filter or export on Kipplo.
Companies
2.7K on file
Biopier, Llc
BioPier is a Boston-based biometrics CRO founded in 2006, 100% USA-based. Our team of experienced biostatisticians and programmers has a proven track record of delivering high-quality studies and (s)NDA/(s)BLA submissions. Our satisfied clients and their referrals are the foundation of our success. BioPier Team BioPier is a team of experienced biostatistical consultants. Team members have an average of 8+ years of experience working in the pharmaceutical industry; the core team has an average of 15+ years. 35% of our team members have Ph.D. degrees, and 95% have earned an M.S. degree or above. The turnover rate within our team is extremely low. BioPier Strength At BioPier, we pride ourselves on our strong reputation for experience and our perfect record of quality on-time delivery. Our clients like us because we are very responsive and easy to work with. BioPier Experience Since 2015, we've been awarded contracts for over 150 studies/contracts in Rare Diseases, Oncology, GI, CNS, Vaccines, and many other therapeutic areas. Most of our studies are late-phase studies. Our exceptional performance has made us the preferred provider for top pharmaceutical companies and has significantly contributed to their (s)NDA/(s)BLA submissions. Examples to showcase our capabilities: From 2019-2022, we helped our clients rescue six pivotal Phase-3 studies. These studies were already at-risk with other CROs, some even in their dry-run stage. We were able to rework them on a very tight schedule and mitigated their risks. About half of our services follow ongoing studies (Phase 1-4), and the rest support submission work like ISS, ISE, HTA, eCRT, FDA-IR, Legacy-to-CDISC migrations, etc. BioPier Service Model BioPier's service model has been project-based and unit-based. We keep our costs low because all sales are from referrals, and we keep a flat and slim reporting structure. The senior staffs directly serve as project managers.
11 to 50 staff
Bostongene
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation.
501 to 1000 staff
California Cryobank Llc
Founded in 1977, California Cryobank pioneered the frozen donor sperm industry in the 1980s and branched into cellular therapies with the launch of FamilyCord in 1997. After acquiring Donor Egg Bank USA in 2016, California Cryobank became the world's largest and most experienced reproductive tissue bank, with the #1 brand in frozen donor sperm and frozen donor egg. California Cryobank is headquartered in Los Angeles, with laboratory/branch offices in Palo Alto, CA, New York, NY, Boston, MA, & Rockville, MD. California Cryobank distributes to all 50 states and over 30 countries, with international partnerships and/or joint ventures throughout Central America, South America, and Europe.
201 to 500 staff
Capsida Biotherapeutics
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D, a neuroscience professor at the California Institute of Technology.
51 to 200 staff
Carolina Biooncology Institute
Carolina BioOncology Institute (CBOI), is a cancer therapy and research center that focuses on early phase immunotherapy trials. Our community-based clinic in Huntersville, NC is the only independent, dedicated Phase I cancer center on the East Coast. CBOI has opened more than 100 early phase clinical trials, has treated almost cancer patients, and serves as a regional referral hub for Phase I access in the community setting. CBOI's business model, includes BioCytics, our internal research and manufacturing organization. It is focused on rapidly and efficiently developing cell therapies using novel processes and unique equipment. We benefit from our fully-integrated capabilities, including basic and translational research, process development, cGMP manufacturing, clinical development, regulatory affairs, USP, CLIA/COLA and operations.
11 to 50 staff
Celcuity
Celcuity is a clinical-stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth. Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Gedatolisib phase 3 clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings. A Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is on-going. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at
51 to 200 staff
Cellibre
Cellibre is a best-in-class manufacturing technology company. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)
11 to 50 staff
Century Therapeutics, Inc
Century Therapeutics is an innovative biotechnology company that is building an industry-leading, allogeneic, iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer. Please note: Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.
51 to 200 staff
Certis Biologicals
Certis Biologicals: Your Partner in Biological Innovation For over 30 years, Certis Biologicals has led the way in developing, manufacturing, and delivering biological solutions for agriculture, turf, greenhouse, home, and garden markets worldwide. With a proven portfolio of biofungicides, bioinsecticides, bionematicides, and plant health products, we empower growers with sustainable, effective crop protection. Our vertically integrated manufacturing facilities ensure consistent quality from plant to field. Backed by extensive research, regulatory expertise, and a dedicated team, Certis Biologicals is trusted by farmers, retailers, and advisors in the U.S. and over 50 countries. Whether integrating biologicals into conventional production or relying solely on sustainable inputs, Certis Biologicals provides solutions that drive resistance management, improve soil health, and enhance crop quality.
51 to 200 staff
Conecraft Llc
ConeCraft is a leading provider of stainless steel equipment for single use systems in biopharmaceutical manufacturing. Specializing in bioprocess container platforms, tube management, and customizable workstations ConeCraft holds patents on technology developed to improve the safety and functionality of equipment throughout the process. With a focus on engineering and tailored solutions, ConeCraft is a preferred supplier to many of the largest biopharma manufacturers and EPCs in world.
51 to 200 staff
Diacarta, Inc
DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. To learn more, visit
11 to 50 staff
Diagnostic Biosystems
Diagnostic BioSystems is a leading developer of specialty Immunohistochemistry reagents. The company is dedicated to high quality antibody production and development of novel multiplex staining reagents. Building on its strong global presence, Diagnostic BioSystems produces novel, clinically relevant tools for pathology market including: monoclonal and polyclonal antibodies, a wide range of detection systems and ancillary reagents for high quality immunostaining. Custom Monoclonal and Polyclonal Antibody Production Services include peptide synthesis, in vitro and in vivo antibody production, purification and conjugation. Diagnostic BioSystems is an FDA registered medical device manufacturer, operating under FDA 21CFR Part 820 Quality System Regulations and certified under ISO 9001:2008 Quality Management System International standards, manufacturing CE marked medical devices, for use in the European market.
51 to 200 staff
Dynport Vaccine Company Llc, A Gdit Company
DynPort Vaccine Company LLC manages product development programs for U.S. and international government agencies, and provides consulting, technical and program management services to companies in the biotechnology and pharmaceutical industries. At DynPort, we're helping the government protect soldiers and civilians against emerging diseases and possible bioterror threats. We're doing important work, protecting our nation’s health and security. Learn more about how we can work together at: View our open positions at https://gdit.com/job-results?key=dvc & loc= & combine_2=All
51 to 200 staff
Encodia
Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.
51 to 200 staff
Endovac Animal Health
Veterinary Biotechnology company involved in research, manufacturing, distributing and marketing vaccines in animal health. Focusing on research allows Endovac Animal Health to have the most advanced technology when it comes to animal health. Please visit our website at
11 to 50 staff
Enzene Biosciences Ltd
Enzene an integrated global CDMO offers services spanning discovery, development and commercial supply. Its patented fully-connected continuous manufacturing (FCCM) platform, EnzeneX™, is validated for commercial biologics supply, and demonstrates significantly increased production yields and reduced costs. Enzene aims to lower mAb production costs below $40/gram by 2025. Visit
501 to 1000 staff
Enzo Life Sciences, Inc
For more than 45 years, Enzo Biochem has been a leader in innovation and product development to support a diverse range of needs in biomedical research and healthcare. With a comprehensive portfolio of high-quality products including antibodies, genomic probes, assays, biochemicals, and proteins, Enzo supports the work of academic research centers and industry partners who are shaping the future of healthcare around the world. The company’s proprietary products and technologies play central roles in all areas of translational research and drug development, including genomic analysis, protein analysis, cellular analysis, tissue analysis, and small molecule chemistry. Enzo Biochem has a broad and deep intellectual property port-folio, with patent coverage across a number of key enabling technologies.
51 to 200 staff
Excelag
ExcelAG, Corp. is an American company founded in 2001, with executive headquarters in Miami, Florida. We are primarily focused on the discovery, research, development and manufacturing of our own product line. We also work closely with customers to design custom made formulas to solve their market needs. ExcelAg, Corpâs portfolio consists of more than 100 brands that are proprietary, innovative, and differentiated. They are marketed in USA and overseas agrochemical and non-agrochemical markets. Our product line includes groups such as: Systemic Plant Nutrition and Bio-Stimulants, SAR Phosphonates, Activation Technology, Performance Enhancers, OMRI certified Organic Pesticides, Plant Growth Regulators, Water Correctors, Soil Correctors, and A large group of innovative Adjuvants All ExcelAG, Corpâs products are manufactured exclusively in USA, and registered in USA and overseas markets. Our technologies have been designed for commercialization in various markets such as Agro, Turf & Ornamentals, Home & Garden, Public Health(including Animal Health), Water treatment, Soil Treatment, Right of ways, Golf Courses, Parks & Amenities, Landscape, etc.
51 to 200 staff
Filtrous
Filtrous is a young company that focuses on supporting analytical chemistry and microbiology laboratories with their consumable needs.
11 to 50 staff
Genecapture, Inc
Detecting Pathogens Takes Too Long Our patented CAPTURE (Confirm Active Pathogens Through Unamplified RNA Expression) technology solves this problem, and we are now developing a portable instrument to screen for hundreds of pathogens within an hour for less than $20. GeneCapture's unique approach to disease diagnostics uses rapid RNA-based technology to bring infection detection to the Point of Care; whether that’s a hospital bed, an airport, a cruise ship, or a battlefield.
11 to 50 staff
Genprex, Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
11 to 50 staff
Glen Research
Glen Research, part of Maravai LifeSciences, is a leading provider of reagents for DNA and RNA oligonucleotide synthesis, labeling, and modification. Known for its proprietary Sterling™ line of reagents marked with its Sterling Seal of Quality Assurance, Glen analyzes and certifies these reagents for purity and performance ensuring consistent, dependable and reliable results. Glen also specializes in oligonucleotide purification supplies under the Glen-Pak™ and Glen Gel-Pak™ product lines. Glen supplies its reagents to: researchers investigating diverse genetic diseases and disorders; businesses and organizations developing new genetic therapies; and, biopharmaceutical, diagnostic and life science OEM partners who incorporate Glen Research offerings into their own products. Glen takes pride in delivering operational excellence, experienced technical support and superior customer service and is ISO 9001:2015 certified. As part of its Quality Management System, Glen verifies that its operations and processes meet all management criteria for consistency and performance. Glen was founded in 1987 by Hugh and Margaret Mackie with a mission to provide state-of-the art reagents to researchers. In 1993, Glen introduced the Sterling line of products, a new standard of accomplishment for oligonucleotide synthesis. Headquartered in Sterling, Virginia, Glen Research is online at
11 to 50 staff
Heidolph North America
Research made easy – empowered by Heidolph Scientific discovery deserves full focus. That’s why we take care of everything else – with intelligent lab solutions, long-lasting technology Made in Germany, and service that’s personal, fast, and reliable. Researchers in over 80 countries trust Heidolph – across pharma, chemistry, biology, and cosmetics – because we offer more than instruments: true partnership, uncompromising quality, and a promise to make research easier. We are proud to be part of the ATS Life Sciences Group, combining our strengths with global expertise in pharmaceutical development, automation, and scalable solutions – for even greater impact and value to our customers. And because great solutions need great people, dedication and precision are at the heart of our global team!
11 to 50 staff
I-Mab Biopharma
I-Mab (NASDAQ: IMAB) is a U.S-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
11 to 50 staff
